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Abstract
Background: Indiscriminate prescription of Benzodiazepines in Pakistan and subsequent availability over-the-counter
without prescription is a major public health problem, requiring systematic inquiry through research. Additionally, there is
limited data on the awareness and use of Benzodiazepines from developing countries making it impossible to devise
meaningful health policies.
Methodology/Principal Findings: This was an Observational, Cross-Sectional study. conducted at Aga Khan University. A
total of 475 (58.5% males, 41.5% females) people visiting a tertiary care hospital were interviewed by means of a structured
questionnaire. The results showed that majority of population was aware of one or more Benzodiazepines (80.4%) and
30.4% had used them at some point in life. 42.4% of the users had been using it for more than a year. Commonest reason
for use was sleep disturbance. Frequency of usage was higher for females, married individuals, educated (.Grade12), high
socioeconomic status and housewives. More (59%) were prescribed than not and of them most by GP (58.5%). Only 36.5%
of them were particularly told about the long-term addiction potential by the use of these drugs.
Conclusion: Easy availability, access to re-fills without prescription and self prescription compounded with the lack of
understanding of abuse potential of benzodiazepines constitutes a significant problem demanding serious consideration
from health policy makers.
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Introduction
Leo Sternbach (1908–2005) is known as the pioneer of
benzodiazepine (BDZ) tranquilizers. His discovery of chlordiaz-
epoxide in 1957 lead to the introduction of a large number of
similar compounds in clinical practice [1]. Today, benzodiaze-
pines are amongst the most widely used group of drugs worldwide
[2].
Benzodiazepines are commonly used for a number of
psychiatric and non-psychiatric reasons some of which include
relief of anxiety and insomnia, treatment of delirium tremens and
other withdrawal syndromes, pre-operative sedation, treatment of
epileptic fits, and relief of muscle spasticity [2,3].
The most common adverse effects associated with benzodiaz-
epines are residual sedation, anterograde amnesia, and rebound
insomnia [4]. These effects are dose related and can therefore be
minimized with dose reduction [5]. Although they are considered
safe and are generally well-tolerated, there is a considerable risk of
misuse and abuse [2].
The occurrence of dependence and withdrawal symptoms is
directly dependant on the duration of use [6]. Most patients with
four months or more of therapy with benzodiazepines experience
some kind withdrawal symptoms including anxiety, dysphoria,
malaise, depersonalization or perceptual changes such as hyper-
acusis and unsteadiness [7].
BDZ prescription and usage is regulated in most developed
countries. This however, does not hold true for developing
countries where such agents are available over-the-counter (OTC)
[2,8,9]. Easy OTC availability and popularity as ‘sleeping pills’
make these agents the preferred drugs for self-poisoning in
Pakistan [9].
BDZ are available over the counter with out prescription. Health
care delivery system is also in shambles. Majority (almost 80%) seek
health care as an out-of-pocket expenditure. Only poorest of the
poor seek health care services from public sector hospitals. Private
health care, for most part is unregulated. BDZ are dispatched
indiscriminately by general physicians–at times with ulterior
motives. Therefore addiction and dependence is a major issue.
There is no research exploring this issue systematically.
The purpose of this study therefore is to assess the awareness
and demographic risk factors associated with BDZ use in Pakistani
population. We also estimate the life-time prevalence of BDZ use
in this population in order to gauge the magnitude of the problems
associated with OTC availability of benzodiazepines.
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Study design
This was an observational, cross sectional study. A question-
naire-based survey was conducted at the Aga Khan Hospital over
a three-week period in October 2004.
Sampling Method and Ethical Concerns
The study was based on a sample of convenience. Systematic
effort was made to obtain data from all consecutive out-patients
and visitors in all major waiting areas of the out-patient
department during business hours 9:00am–5:00pm. Three ran-
dom weekdays were chosen (in a three week period) for this
purpose. The number of those who refused to participate, reason
for refusal and their demographics were not recorded. Exclusion
criteria included age less than 15 years, all inpatients, psychiatry
clinic outpatients, medical professionals, health employees and
their family members.
Since our study was not experimental and did not involve any
intervention, we did not approach an ethics committee for review
before conducting the study. We took informed consent from all
participants and maintained strict confidentiality. All possible
ethical concerns were discussed with the supervising faculty in the
Department of Psychiatry at our University. All ethical principles
of the Helsinki Declaration were followed.
Data Collection
There is no research exploring this issue systematically. Thus no
questionnaires were available that explore the issue from public
health or mental health perspective. Since conditions pertaining to
use of BDZ are unique in Pakistan, we decided to design our own
instrument. This was done in consultation with the experts in the
field of psychiatry and public health. It was designed to assess
various aspects of knowledge, practices and attitude towards the
use of benzodiazepines. As the questionnaire was self-administered
it was translated in the local language (Urdu) and piloted. The
interviewers were trained in both English and Urdu for
standardization.
To assess knowledge regarding benzodiazepines, subjects were
asked if they recognize the names of some of the commonly
prescribed BDZ. Those who had recognized the name of at least
one of the commonly prescribed BDZ were further asked if they
thought these drugs are harmful. Further questioning regarding
practices and attitude was not possible in those who failed to
recognize the name of any of the commonly used benzodiazepines
Those who had heard of a BDZ were further divided into two
groups depending on usage of the drug (i.e. those who had used
benzodiazepines and those who had not used benzodiazepines).
All subjects who had used or were currently using these
medications were asked about the drug(s) they had used, the
reason and duration of use.
In order to assess the prescription practices, subjects were
further asked whether the drug(s) had been prescribed or if they
had been self medicating, designation of prescribing physician, if
they had been informed about the side effects of these drugs or not
and finally, if they had been specifically warned about their
addiction potential or not.
Analysis
The data was tabulated and analyzed in SPSS (version 12.0).
Descriptive statistics were obtained on responses to each question.
Chi square test, Student’s t-test and one way ANOVA were used
for inferential statistics.
Results
Demographics
In this study 475 individuals participated. Mean age of the
population was 35.64611.06 years. 58.5% were males (n=278)
and 41.5% were females (n=197). Majority were married (73.5%)
as opposed to single (26.5%). Most of the subjects were housewives
(30.3%) or professionals (20%) among others. 49% of the study
population comprised of people from medium income group (Rs
5000–25000/mo), 24% from high income group (.Rs 25000) and
19.6% from low income group (,Rs 5000). Important demo-
graphic measures are summarized in Table 1
Knowledge
Of the sampled population 80.4% had heard of a BDZ.
Proportion of males (84.5%) who had heard of one or more drugs
was significantly greater than proportion of females (74.6%) who
had heard of one or more drugs (p,0.05). There was a significant
association (p=0.018) between occupation and those who had
heard of a BDZ (Professionals 88.4%, Laborers 84.1%, Business-
men 83.3%, house-wives 74.3%, Students 73.7%, Unemployed
66.7%).
The results demonstrated that 86% of the high income (.Rs
25000/mo) group had heard of a BDZ compared with 82% and
65% of the middle (Rs 5000–25000/mo) and low income (,Rs
5000/mo) group respectively (p,0.001). Education was signifi-
cantly associated (p,0.001) with the awareness of the name of a
BDZ (Graduate and above 90.4%; up to secondary 77.6%;
primary or less 53.5%). The data however, failed to show an
association of age and marital status with the awareness of the
name of a BDZ.
Table 1. Demographic Distribution (n=475)
Variable Subcategory Frequency (%)
Gender Male 278 (58.5)
Female 197 (41.5)
Age (years) 1 (16–27) 148 (31.2)
2 (28–39) 166 (34.9)
3 (40–51) 102 (21.5)
4 (52–63) 42 (8.8)
5 (64–75) 15 (3.2)
Marital status Married 349 (73.5)
single 126 (26.5)
Occupation Housewife 144 (30.3)
Professionals 95 (20.0)
Businessmen 66 (13.9)
Students 57 (12.0)
Laborers 44 (9.3)
Unemployed 21 (4.4)
Income per month Low (,Rs 5000) 93 (19.6)
Medium (Rs 5000–25000) 233 (49.1)
High (.Rs 25000) 114 (24.0)
Education Primary or less 71 (14.9)
Secondary 165 (34.7)
Graduate and above 239 (50.3)
doi:10.1371/journal.pone.0001804.t001
Awareness&Use-Benzodiazepines
PLoS ONE | www.plosone.org 2 March 2008 | Volume 3 | Issue 3 | e1804Of those who had heard of one or more of the drugs 68.9%
thought that they can be harmful, 17.3 % did not think so while
13.8% did not know if they can be harmful or not. There was a
significant association between awareness of harm and education
(p,0.001) i.e. 77.8% of graduates and above, 63.8% of those
educated up to secondary and 35.1% of those educated up to
primary or less thought that BDZ can cause harm.
Attitudes and Practices
In overwhelming majority (58.1%), the source of information
regarding benzodiazepines were family and friends. Others learnt
about the drugs from general physicians (18.3%), specialist
physicians (4.2%) and through media (3.9%) and psychiatrists
(1.6%).
The life time prevalence of use was reported to be 30.4%
(n=144). Of them, 33 had used multiple medications. The
commonly used medications were Alprazolam(37.9%), Bromaze-
pam(34.5%), Diazepam(10.7%), Lorazepam(8.4%) among others
(30.3%). Commonly reported reasons for use were sleeplessness
(68.3%), stress or anxiety (52.2%), ghabrahat–a cluster of symptoms
that includes a vague sense of uneasiness, fidgetiness, restlessness
or impending doom (10.9%), and depression (7%). Percentages
may not add up to 100% because of multiple responses by each
respondent to the questions regarding source of information, name
of drug used and reason for use.
In our study mean age of those using BDZ was higher
(41.6613.6 yrs) when compared with the non-users (33610.5 yrs)
(p,0.001). More married individuals were using BDZ then single
(34% vs. 20%). Among all the professional groups, homemakers
(Housewives) were particularly prone to the use of BDZ
(p=0.001). Income level was also a significant variable
(p,0.001) influencing BDZ use; highest in the high income group
(42.5%) with decreasing use in middle (27.9%) and low income
groups (20.7%). Higher educational status was associated with the
use of BDZ (p=0.003). Inferences regarding usage of benzodiaz-
epines and various demographic variables along with p-values are
summarized in Table 2.
Most of the users (59%) reported that the drugs were prescribed
to them by health care provider at some point in time; 58.8% of
them were prescribed by GP, 35.3% by specialists, 5.9% by
psychiatrists. Of those who were prescribed, 41.2% were informed
about the side effects of these drugs and 36.5% were particularly
told about the long-term addiction potential. The study failed to
show an association between provision of information and the
category of prescribing physician which may be due to lack of
power to show a significant association.
The greatest proportion of users had taken the drug for more
than one year (42.4%). 23.6% of people had used it for a month or
less and 11.8% had used it for more than a month (but less than a
year). 22.3% did not remember the exact duration of use.
Discussion
This is the first study from Pakistan that reports prevalence
estimates of BDZ use in a non-admitted population, describing
socio-demographic correlates.
The life-time prevalence of BDZ use was 30.4% in our data.
This is much greater than that of USA (4.1%)[10]. The life-time
prevalence in a multi-center study across Brazil was reported to be
3.3%[11]. Our data is comparable to life-time prevalence reported
from Chile (28.4%)[12].
BDZ usage was more common in females (37.8% vs. 25.3% in
males) and the users tended to be older. This is consistent with
studies from developed countries [13,14,15,16]. When data (not
shown) was stratified to elderly ($60 years) and non-elderly
(,60 years), we failed to show an association between these sub-
groups and BDZ usage. This may be explained by the small
Table 2. Characteristics of persons who reported BDZ use
Variable Sub-category
Percentage use in
each subcategory Mean6Std. dev P-value
Gender Male 25.3 p,0.05
Female 37.8
Age (years) BDZ users 41.65613.57 p,0.001*
BDZ non-users 33.03610.54
Marital status Married 34 p,0.05
single 20.6
Occupation Housewife 39.9 p=0.001
Professionals 25.3
Students 24.6
Businessmen 22.7
Laborers 20.5
Unemployed 10
Income per month Low (,Rs 5000) 20.7 p,0.05
Medium (Rs 5000–25000) 27.9
High (.Rs 25000) 42.5
Education Primary or less 15.7 p=0.003
Secondary 28
Graduate and above 36.4
*Student’s t-test; For the analysis of remaining variables Chi-square test was employed
doi:10.1371/journal.pone.0001804.t002
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to show a significant association. BDZ use was higher in married
people as compared to single in our cohort. This is contrary to the
finding reported by Swartz et al. who found that BDZ use was
higherinseparatedordivorced NorthAmericans[14]. Ourfindings
are consistent with earlier studies that have reported marriage as a
psychosocial risk factor for mental illnesses in Pakistan [17].
We observed that people who had high income and higher
education comprised a greater proportion of BDZ users. Swartz et
al. reported higher use in less educated whereas Neutel et al. have
reported higher use in those North Americans who have
completed high school [14,16]. Approximately 40% of the house
wives used BDZ at some point in their life. This may be explained
by studies that have reported marriage as a psychosocial correlate
for mental illness in Pakistan as discussed above. Only 10% of
unemployed men had used BDZ which is contrary to the higher
rate reported by Parma et al [13].
Contrary to the prescription practices in developed countries,
we observed that only 59% of BDZ users were prescribed these
agents at some point [2]. Only 36.5% of these, however, were
informed about the long term abuse potential of benzodiazepines.
This fact underscores the importance of physicians educating their
patients about the long term abuse potential of benzodiazepines
especially where patients have easy OTC access to these agents.
Long term use (.1 year) was seen in 42.4% of BDZ users in our
study. Magrini et al. and Lyndon et al. have described long-term
use (.6 months) in 56% and 82% of Italian and rural Australian
users respectively [13,15]. Neutel et al. observed that 53.2% of
BDZ users continue using these agents for at least 2 years [18].
Commonest reason for use was sleeplessness/insomnia closely
followed by anxiety. This is consistent with the European data
reported by Lader et al [19].
It was interesting to note that, a significantly greater proportion
of non-users (61%) as opposed to users (39%) thought that these
drugs may cause some kind of harm (p,0.001). This highlights the
importance of awareness programs and primary prevention.
However, among those who particularly knew that these drugs
can be abused, 68.7 % were users. Long term users of BDZ most
likely have had the opportunity to acquire specific knowledge of
abuse, side effects and brand names. It is also possible that they
need to use these medications for clinical reasons despite the
awareness of abuse potential.
The findings of this study need to be interpreted with caution as
this is not a community based survey. Since the sample was drawn
from a non-admitted population (healthy volunteers and ambu-
latory patients) visiting a tertiary care hospital, the life-time
prevalence may be an overestimate. Similarly, care should be
taken when generalizing these findings to urban Pakistani
population. Demographics of our sample population closely match
the national health survey of Pakistan data on age distribution,
socioeconomic status and marital status. However our sample had
more literate and more male individuals than the national average
[20]. This may be partly explained by less number of females
visiting the tertiary care center and their reluctance to be
interviewed. Data for frequency of BDZ use was not recorded
and this could be a potential limitation. We interviewed visitors
and patients in ambulatory areas. Therefore some of them might
have health issues which may confound our findings. We made a
deliberate effort to minimize this by excluding psychiatry out-
patients. Given the seriousness of this issue and in the absence of
any other data, these findings are important and relevant.
Our data suggests that the lay Pakistani population is poorly
educated regarding the risks and abuse potential of BDZ
medications. The main source of information regarding BDZ is
family and friends. Furthermore, 41% of individuals using BDZ
had obtained these medications OTC, without a doctor’s
prescription. Even amongst those BDZ users who had received
these medications through a physician, only one-third were aware
of the long term abuse potential. Hence our data, in light of the
easy availability of BDZ in Pakistan, suggests a grave public health
risk for BDZ misuse and abuse. We and others[8] believe that
there is a dire need to regulate availability of such agents over the
counter. We hereby suggest a REPAIR strategy to deal with this
problem. (Regulate OTC availability; physicians must Emphasize
abuse potential while prescribing; Prescribe judicially and only
when needed; Awareness programs for general population
targeting vulnerable groups; Identification of people with depen-
dence and their Rehabilitation).
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